20:03 , Jul 6, 2018 |  BioCentury  |  Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Financial News

AbGenomics completes venture financing

AbGenomics International Inc. , Los Altos, Calif.   Business: Antibodies   Date completed: 2014-08-27   Type: Venture financing   Raised: $13.2 million   Note: The company raised $13.2 million, according to an SEC filing.  ...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

AbGenomics, Boehringer Ingelheim deal

In December, AbGenomics said it will regain rights to AbGn-168H from Boehringer Ingelheim, effective Feb. 13. The companies mutually terminated the 2005 deal giving Boehringer exclusive, worldwide rights to develop and commercialize the humanized mAb...
07:00 , Jun 13, 2005 |  BC Week In Review  |  Company News

AbGenomics Corp., Boehringer Ingelheim deal

AbGenomics granted Boehringer Ingelheim an exclusive worldwide license to develop and commercialize antibody 168. The humanized MAb initially will be developed for autoimmune indications. The companies did not disclose when the product will enter the...
07:00 , Jun 13, 2005 |  BioCentury  |  Tools & Techniques

Targeted T cell death

The abnormal activation of T cells underpins chronic inflammatory responses, leading to conditions such as autoimmune diseases, allergic reactions, transplant rejection and graft-versus-host disease (GvHD). While immunosupressants can control aggressive T cells, their long-term use...
00:51 , Jun 7, 2005 |  BC Extra  |  Company News

Boehringer Ingelheim licenses AbGenomics antibody

AbGenomics (Taipei, Taiwan) granted Boehringer Ingelheim (Ingelheim, Germany) an exclusive worldwide license to develop and commercialize antibody 168 for all indications. The humanized MAb will initially be developed for autoimmune indications. The companies did not...